Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome (ACTION)
Primary Purpose
Evans Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
blood sample
Sponsored by
About this trial
This is an interventional diagnostic trial for Evans Syndrome focused on measuring pediatric Evans Syndrome, genetic causes, immunophenotyping immunologic explorations
Eligibility Criteria
Inclusion Criteria:
- Patient registered in the French national prospective OBS'CEREVANCE cohort
- Diagnosis of pediatric Evans syndrome (PTI+AHAI)
- Age strictly under 18 years at the initial onset
- Child residing in metropolitan France and affiliated to a french health insurance system
- Free, informed, written and signed consent
Exclusion Criteria:
- Evans syndrome secondary to chemotherapy, bone marrow transplantation or organ transplantation.
- Refusal to participate from parents/patients
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
pediatric Evans Syndrome
Arm Description
Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
Outcomes
Primary Outcome Measures
Number of patients for whom a causal mutation has been identified (known or new)
The number of biological samples collected for PSE children included in the OBS'CEREVANCE cohort and their relatives will be recorded
Secondary Outcome Measures
Immunopathological clinical manifestations
Abnormalities of lymphocyte immunophenotyping
The correlation between causal mutations identified with the clinical and immunological phenotype
Physiopathological and potentially therapeutic classification of pES-T
Full Information
NCT ID
NCT03912129
First Posted
April 9, 2019
Last Updated
April 9, 2019
Sponsor
University Hospital, Bordeaux
Collaborators
Institut des maladies génétiques, Paris
1. Study Identification
Unique Protocol Identification Number
NCT03912129
Brief Title
Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome
Acronym
ACTION
Official Title
Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
May 6, 2019 (Anticipated)
Primary Completion Date
May 6, 2022 (Anticipated)
Study Completion Date
May 6, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Institut des maladies génétiques, Paris
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Characterization of the genetic causes, and of the immunopathological clinical and biological manifestations in children with pediatric Evans syndrome included in a prospective national observational cohort of rare diseases.
Detailed Description
Pediatric Evans syndrome (pES) is a rare and severe disease combining immunologic thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA). French patients from the 30 hematologic pediatric centers are from 2004 included in a prospective national OBS'CEREVANCE cohort.
A first pilot study revealed a monogenic cause in 7/18 patients (40%) with mutations in the CTLA-4, LRBA, STAT3 GOF, and KRAS. TNGS or exome studies were performed between 2015 and 2018 inn 80 patients with pSE from the OBS'CEREVANCE cohort. This approach, combined with by immunophenotyping lymphocyte, identified a genetic cause of the disease in 26 patients (32%) (TNFRSF6, CTLA4, LRBA, STAT3 GOF, PIK3CD, RAG1, KRAS) and potential causal mutations in 18 other patients (22%), bringing the proportion of potential single gene cause to 76%.
The central hypothesis of this study is that most, if not all, cases of pSE are related to a monogenic or digenic cause, possibly with the intervention of genetic modifiers such as somatic mutations.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Evans Syndrome
Keywords
pediatric Evans Syndrome, genetic causes, immunophenotyping immunologic explorations
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
pediatric Evans Syndrome
Arm Type
Other
Arm Description
Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
Intervention Type
Genetic
Intervention Name(s)
blood sample
Intervention Description
A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity.
In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE.
In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing .
If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants.
Primary Outcome Measure Information:
Title
Number of patients for whom a causal mutation has been identified (known or new)
Time Frame
after the genetic analyzes carried out on all the participants included, may 2022
Title
The number of biological samples collected for PSE children included in the OBS'CEREVANCE cohort and their relatives will be recorded
Time Frame
every 3 months, between may 2019 and may 2022
Secondary Outcome Measure Information:
Title
Immunopathological clinical manifestations
Time Frame
after the genetic analyzes carried out on all the participants included, may 2022
Title
Abnormalities of lymphocyte immunophenotyping
Time Frame
after the genetic analyzes carried out on all the participants included, may 2022
Title
The correlation between causal mutations identified with the clinical and immunological phenotype
Time Frame
after the genetic analyzes carried out on all the participants included, may 2022
Title
Physiopathological and potentially therapeutic classification of pES-T
Time Frame
after the genetic analyzes carried out on all the participants included, may 2022
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient registered in the French national prospective OBS'CEREVANCE cohort
Diagnosis of pediatric Evans syndrome (PTI+AHAI)
Age strictly under 18 years at the initial onset
Child residing in metropolitan France and affiliated to a french health insurance system
Free, informed, written and signed consent
Exclusion Criteria:
Evans syndrome secondary to chemotherapy, bone marrow transplantation or organ transplantation.
Refusal to participate from parents/patients
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nathalie Aladjidi, M.D
Phone
05 57 82 02 79
Email
nathalie.aladjidi@chu-bordeaux.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Aurore CAPELLI, PhD
Phone
05 57 82 08 77
Email
aurore.capelli@chu-bordeaux.fr
12. IPD Sharing Statement
Learn more about this trial
Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome
We'll reach out to this number within 24 hrs